# Swiss dental startup vVardis shares slide 7% in NYSE debut as tech selloff roils IPO market

- URL: https://talkfuse.com/story/swiss-dental-startup-vvardis-shares-slide-7-in-nyse-debut-as-tech-selloff-roils-ipo-market/
- Published: 2026-11-13T18:42:58+00:00
- Updated: 2026-11-13T19:35:44+00:00
- Original publisher: New York Post (publisher lean: Right)
- Original article: https://nypost.com/2026/11/13/business/vvardis-shares-slide-7-in-nyse-debut/
- Topics: Business, Companies, Markets, World

## Key points

- vVardis shares fell 7% in their NYSE debut.
- The IPO raised $175 million at $18 a share.
- Its flagship treatment’s sales rose 112%.

## Summary

Swiss dental health company vVardis fell 7% in its New York Stock Exchange debut, after pricing its shares below the range it had marketed to investors. The weak start reflects pressure on new listings as a technology selloff and uncertainty about AI-related spending and regulation make investors more cautious about valuations.

The Zug-based firm raised $175 million by selling 9.7 million shares at $18 each, against a target of $21 to $24; shares opened at $14 and later traded below $17. Founded in 2020 by sisters Haley and Goly Abivardi, vVardis makes Curodont treatments intended to reverse early tooth decay without drilling or injections. Sales of its flagship US product rose 112% in the nine months to 30 September, and it was available at more than 20,000 US dental practices as of 30 June.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.